Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Tumor-Infiltrating Lymphocytes And Prognosis: A Pooled Individual Patient Analysis Of Early-Stage Triple-Negative Breast Cancers.

S. Loi, D. Drubay, S. Adams, G. Pruneri, P. Francis, M. Lacroix-triki, H. Joensuu, M. V. Dieci, S. Badve, S. Demaria, R. Gray, E. Munzone, J. Lemonnier, C. Sotiriou, M. Piccart, P. Kellokumpu-Lehtinen, A. Vingiani, K. Gray, F. André, C. Denkert, R. Salgado, S. Michiels
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). METHODS Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33% of patients were node negative. The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). A total of 736 iDFS and 548 D-DFS events and 533 deaths were observed. In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ2, 48.9 iDFS; P < .001; χ2, 55.8 D-DFS; P < .001; χ2, 48.5 OS; P < .001). Each 10% increment in sTILs corresponded to an iDFS hazard ratio of 0.87 (95% CI, 0.83 to 0.91) for iDFS, 0.83 (95% CI, 0.79 to 0.88) for D-DFS, and 0.84 (95% CI, 0.79 to 0.89) for OS. In node-negative patients with sTILs ≥ 30%, 3-year iDFS was 92% (95% CI, 89% to 98%), D-DFS was 97% (95% CI, 95% to 99%), and OS was 99% (95% CI, 97% to 100%). CONCLUSION This pooled data analysis confirms the strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sTILs in a clinicopathologic prognostic model for patients with TNBC. This model can be found at www.tilsinbreastcancer.org .
This paper references
10.1126/scitranslmed.aal4922
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
E. Nolan (2017)
10.1056/NEJMoa1510764
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
J. Sparano (2015)
10.1073/pnas.1104303108
Leukocyte composition of human breast cancer
B. Ruffell (2011)
10.1126/science.aaa4971
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
10.1200/JCO.2014.58.1967
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
C. Denkert (2015)
10.1007/s10549-016-3863-3
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
G. Pruneri (2016)
10.1093/annonc/mdu450
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R. Salgado (2015)
10.1016/j.immuni.2014.10.017
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
S. Woo (2014)
10.1200/JCO.2011.41.0902
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
S. Loi (2013)
10.1007/s10549-017-4499-7
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer
Roberto A. Leon-Ferre (2017)
10.1093/annonc/mdu112
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S. Loi (2014)
10.1200/JCO.2013.55.0491
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
S. Adams (2014)
10.1093/annonc/mdv571
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
G. Pruneri (2016)
10.1016/j.cell.2016.03.001
Microbiome and Anticancer Immunosurveillance
L. Zitvogel (2016)
10.1038/nrclinonc.2015.215
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
P. Savas (2016)
10.1093/annonc/mdu191
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
H. R. Ali (2014)
10.1093/annonc/mdv239
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
M. V. Dieci (2015)
10.1038/modpathol.2016.109
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
C. Denkert (2016)
10.1093/annonc/mdv106
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
S. Gourgou-Bourgade (2015)
10.1073/pnas.1609376113
Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
Stefani Spranger (2016)
10.1200/JCO.2006.07.3916
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
H. Roché (2006)
10.1136/bmj.i3140
External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges
R. Riley (2016)



This paper is referenced by
10.26442/18151434.2019.3.190655
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
K. S. Grechukhina (2019)
10.1007/s10549-019-05390-x
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer
A. I. Hida (2019)
10.3390/cancers12051076
Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women
Yong Won Jin (2020)
10.7150/jca.35109
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
L. Pizzuti (2019)
10.1016/j.cytogfr.2019.12.002
Anticancer innovative therapy: Highlights from the ninth annual meeting.
T. Volpari (2019)
10.1007/s10549-020-05861-6
Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type
J. Kim (2020)
10.1093/annonc/mdz201
The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
S. Loi (2019)
10.1136/esmoopen-2019-000515
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
Mariana Brandão (2019)
10.1016/j.ctrv.2020.102064
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.
M. V. Dieci (2020)
10.26508/lsa.201900562
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer
Alaknanda Adwal (2020)
10.6004/jnccn.2020.7554
Role of Immunotherapy in Triple-Negative Breast Cancer.
T. Keenan (2020)
10.1038/s41573-020-0077-5
Targeting the epigenetic regulation of antitumour immunity
S. J. Hogg (2020)
10.1093/annonc/mdz115
T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
A. Marra (2019)
10.1007/s40139-020-00217-7
Characterizing Immune Responses in Whole Slide Images of Cancer With Digital Pathology and Pathomics
Rajarsi Gupta (2020)
10.1136/jitc-2019-000162
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
M. Eckstein (2020)
10.1158/1078-0432.CCR-19-0285
Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
D. Hammerl (2019)
10.1097/SLA.0000000000003551
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
C. Karakas (2019)
10.1097/CCO.0000000000000675
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer
Jack Junjie Chan (2020)
10.3233/BD-200442
Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
M. Pujani (2020)
10.3390/cancers12040819
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
A. Diana (2020)
10.3390/cancers12061404
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
J. S. Lee (2020)
10.13345/j.cjb.190300
[Function of tumor infiltrating lymphocytes in solid tumors - a review].
Suhang Bai (2019)
10.1016/j.intimp.2020.106506
Prognosis significance of Indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Li-juan Wei (2020)
10.1038/s41523-019-0133-7
If we build it they will come: targeting the immune response to breast cancer
M. Gatti-Mays (2019)
10.1155/2020/5618786
Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
Masanori Oshi (2020)
10.1186/s12885-020-06949-4
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer
R. Wesolowski (2020)
A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study.
Sarah N. Dudgeon (2020)
10.1186/s13058-020-01285-8
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
Signe Korsgaard Skriver (2020)
10.1080/14737140.2019.1699066
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer
C. Corvaja (2019)
10.1007/s10549-020-05913-x
Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes
Frederik Deman (2020)
10.1186/s13058-019-1171-7
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
Bradley A. Hancock (2019)
10.21037/WHI.2019.03.01
Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?
Elvire Pons-Tostivint (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar